ZA200407665B - New compounds. - Google Patents
New compounds. Download PDFInfo
- Publication number
- ZA200407665B ZA200407665B ZA200407665A ZA200407665A ZA200407665B ZA 200407665 B ZA200407665 B ZA 200407665B ZA 200407665 A ZA200407665 A ZA 200407665A ZA 200407665 A ZA200407665 A ZA 200407665A ZA 200407665 B ZA200407665 B ZA 200407665B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyridin
- compound
- hydroxy
- indol
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 154
- 238000006243 chemical reaction Methods 0.000 claims description 51
- 229910052717 sulfur Inorganic materials 0.000 claims description 46
- 229910052760 oxygen Inorganic materials 0.000 claims description 45
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 40
- 229910052736 halogen Inorganic materials 0.000 claims description 40
- 150000002367 halogens Chemical group 0.000 claims description 40
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 39
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 38
- 125000005842 heteroatom Chemical group 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 230000002265 prevention Effects 0.000 claims description 35
- -1 (CO)OC Chemical group 0.000 claims description 33
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 29
- 239000002904 solvent Substances 0.000 claims description 28
- 239000002585 base Substances 0.000 claims description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 22
- 208000024827 Alzheimer disease Diseases 0.000 claims description 20
- 239000000460 chlorine Substances 0.000 claims description 19
- 208000010877 cognitive disease Diseases 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 206010012289 Dementia Diseases 0.000 claims description 18
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
- 229920006395 saturated elastomer Polymers 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 16
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 229910052801 chlorine Inorganic materials 0.000 claims description 16
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 15
- 229910052731 fluorine Inorganic materials 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 13
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 13
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 13
- 239000011737 fluorine Substances 0.000 claims description 13
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims description 13
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 13
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 12
- 206010027175 memory impairment Diseases 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 201000004384 Alopecia Diseases 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000020925 Bipolar disease Diseases 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 239000012458 free base Substances 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims description 7
- 208000028698 Cognitive impairment Diseases 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- 206010019196 Head injury Diseases 0.000 claims description 6
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 6
- 206010034010 Parkinsonism Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 230000003676 hair loss Effects 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 5
- 201000010374 Down Syndrome Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000019022 Mood disease Diseases 0.000 claims description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 5
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 5
- 230000006999 cognitive decline Effects 0.000 claims description 5
- 239000003433 contraceptive agent Substances 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 208000017004 dementia pugilistica Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 208000024963 hair loss Diseases 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 206010068168 androgenetic alopecia Diseases 0.000 claims description 4
- 201000002996 androgenic alopecia Diseases 0.000 claims description 4
- 230000002254 contraceptive effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 claims description 3
- 201000004810 Vascular dementia Diseases 0.000 claims description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 3
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- APRYBBRXBYNGRD-WLHGVMLRSA-N (E)-but-2-enedioic acid 3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-5-(1,3-thiazol-4-yl)-1H-indol-2-ol Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCN1S(=O)(=O)c1ccc(-c2c([nH]c3ccc(cc32)-c2cscn2)O)nc1 APRYBBRXBYNGRD-WLHGVMLRSA-N 0.000 claims description 2
- QCYPSFQGPOIENZ-WLHGVMLRSA-N (E)-but-2-enedioic acid 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-(2-pyrrolidin-1-ylethyl)pyridine-3-carboxamide Chemical compound OC(=O)\C=C\C(O)=O.Oc1[nH]c2ccc(C#N)cc2c1-c(nc1)ccc1C(=O)NCCN1CCCC1 QCYPSFQGPOIENZ-WLHGVMLRSA-N 0.000 claims description 2
- RXYFRVCSXAWEJR-WLHGVMLRSA-N (E)-but-2-enedioic acid 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide Chemical compound OC(=O)\C=C\C(O)=O.CCN1CCCC1CNS(=O)(=O)C1=CC=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=C1 RXYFRVCSXAWEJR-WLHGVMLRSA-N 0.000 claims description 2
- FZVZMDOGYBGFTL-WLHGVMLRSA-N (E)-but-2-enedioic acid 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide Chemical compound OC(=O)\C=C\C(O)=O.N1=CC(S(=O)(=O)N(CCN(C)C)CC)=CC=C1C1=C(O)NC2=CC=C(C#N)C=C12 FZVZMDOGYBGFTL-WLHGVMLRSA-N 0.000 claims description 2
- ZFRDGCKDAKVMRW-WLHGVMLRSA-N (E)-but-2-enedioic acid [6-(2-hydroxy-5-nitro-1H-indol-3-yl)pyridin-3-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCN1C(=O)c1ccc(-c2c([nH]c3ccc(cc32)[N+]([O-])=O)O)nc1 ZFRDGCKDAKVMRW-WLHGVMLRSA-N 0.000 claims description 2
- HGCLVHWOIGDXAZ-UHFFFAOYSA-N 2-hydroxy-3-(5-morpholin-4-ylsulfonylpyridin-2-yl)-1H-indole-5-carbonitrile Chemical compound OC=1NC2=CC=C(C#N)C=C2C=1C(N=C1)=CC=C1S(=O)(=O)N1CCOCC1 HGCLVHWOIGDXAZ-UHFFFAOYSA-N 0.000 claims description 2
- TUHYCRZRVGKOJC-UHFFFAOYSA-N 2-hydroxy-3-[4-(4-methylpiperazine-1-carbonyl)pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)C1=CC=NC(C=2C3=CC(=CC=C3NC=2O)C#N)=C1 TUHYCRZRVGKOJC-UHFFFAOYSA-N 0.000 claims description 2
- AGWBFQVRRSLCHJ-UHFFFAOYSA-N 2-hydroxy-3-[5-(4-methylpiperazine-1-carbonyl)pyridin-2-yl]-1H-indole-5-carbonitrile Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=C1 AGWBFQVRRSLCHJ-UHFFFAOYSA-N 0.000 claims description 2
- QEGKDXPEXXJSBJ-UHFFFAOYSA-N 2-hydroxy-3-[5-(4-propan-2-ylpiperazin-1-yl)sulfonylpyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride Chemical compound Cl.C1CN(C(C)C)CCN1S(=O)(=O)C1=CC=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=C1 QEGKDXPEXXJSBJ-UHFFFAOYSA-N 0.000 claims description 2
- BBGBUCAWBPAOKB-UHFFFAOYSA-N 2-hydroxy-3-[5-(pyrrolidin-1-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile Chemical compound OC=1NC2=CC=C(C#N)C=C2C=1C(N=C1)=CC=C1CN1CCCC1 BBGBUCAWBPAOKB-UHFFFAOYSA-N 0.000 claims description 2
- PNSRYCSDXDXFBB-UHFFFAOYSA-N 2-hydroxy-3-[5-[(3-methylpiperidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile Chemical compound C1C(C)CCCN1CC1=CC=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=C1 PNSRYCSDXDXFBB-UHFFFAOYSA-N 0.000 claims description 2
- VBOGGFCZFUJSMT-UHFFFAOYSA-N 2-hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride Chemical compound Cl.C1CN(C)CCCN1CC1=CC=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=C1 VBOGGFCZFUJSMT-UHFFFAOYSA-N 0.000 claims description 2
- AICZIXZCGTTZLV-UHFFFAOYSA-N 2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride Chemical compound Cl.C1CN(C)CCN1CC1=CC=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=C1 AICZIXZCGTTZLV-UHFFFAOYSA-N 0.000 claims description 2
- GPTISHQYMJHWON-UHFFFAOYSA-N 2-hydroxy-3-[5-[(4-methylpiperidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile Chemical compound C1CC(C)CCN1CC1=CC=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=C1 GPTISHQYMJHWON-UHFFFAOYSA-N 0.000 claims description 2
- KPMVLWSSNOTENQ-UHFFFAOYSA-N 2-hydroxy-3-[5-[(4-phenylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile Chemical compound OC=1NC2=CC=C(C#N)C=C2C=1C(N=C1)=CC=C1CN(CC1)CCN1C1=CC=CC=C1 KPMVLWSSNOTENQ-UHFFFAOYSA-N 0.000 claims description 2
- BCJXCAKHQLKPLH-UHFFFAOYSA-N 2-hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1H-indole-5-carbonitrile Chemical compound OC=1NC2=CC=C(C#N)C=C2C=1C(N=CN=1)=CC=1OCCN1CCOCC1 BCJXCAKHQLKPLH-UHFFFAOYSA-N 0.000 claims description 2
- CCRQRQITUSYUCY-UHFFFAOYSA-N 3-[3-bromo-5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-5-nitro-1H-indol-2-ol hydrochloride Chemical compound Cl.C1CN(C)CCN1S(=O)(=O)C(C=C1Br)=CN=C1C1=C(O)NC2=CC=C([N+]([O-])=O)C=C12 CCRQRQITUSYUCY-UHFFFAOYSA-N 0.000 claims description 2
- AUBFRFKDPRVUMI-UHFFFAOYSA-N 3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-1H-indol-2-ol hydrochloride Chemical compound Cl.C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2C3=CC=CC=C3NC=2O)N=C1 AUBFRFKDPRVUMI-UHFFFAOYSA-N 0.000 claims description 2
- XYUBCWOJCJVECF-UHFFFAOYSA-N 3-[5-(azetidin-1-ylmethyl)pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile Chemical compound OC=1NC2=CC=C(C#N)C=C2C=1C(N=C1)=CC=C1CN1CCC1 XYUBCWOJCJVECF-UHFFFAOYSA-N 0.000 claims description 2
- JNWPMVNHJYNDFH-UHFFFAOYSA-N 3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-5-(trifluoromethyl)-1H-indol-2-ol Chemical compound OC=1NC2=CC=C(C(F)(F)F)C=C2C=1C(N=C1)=CC=C1CN1CCOCC1 JNWPMVNHJYNDFH-UHFFFAOYSA-N 0.000 claims description 2
- LCXBCMKWUPCGNT-UHFFFAOYSA-N 3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-5-thiophen-2-yl-1H-indol-2-ol hydrochloride Chemical compound Cl.OC=1NC2=CC=C(C=3SC=CC=3)C=C2C=1C(N=C1)=CC=C1CN1CCOCC1 LCXBCMKWUPCGNT-UHFFFAOYSA-N 0.000 claims description 2
- VJUKIBVGYYABIY-UHFFFAOYSA-N 3-[5-[[(4-chlorophenyl)methyl-methylamino]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile Chemical compound C=1C=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=CC=1CN(C)CC1=CC=C(Cl)C=C1 VJUKIBVGYYABIY-UHFFFAOYSA-N 0.000 claims description 2
- BZSXDPUXOKMIHP-UHFFFAOYSA-N 3-[5-[[2-cyanoethyl(ethyl)amino]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile Chemical compound N1=CC(CN(CCC#N)CC)=CC=C1C1=C(O)NC2=CC=C(C#N)C=C12 BZSXDPUXOKMIHP-UHFFFAOYSA-N 0.000 claims description 2
- DGYOQSAUPDVPQH-UHFFFAOYSA-N 3-fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxo-1h-indole-6-carbonitrile;hydrochloride Chemical compound Cl.O=C1NC2=CC(C#N)=CC=C2C1(F)C(N=C1)=CC=C1CN1CCOCC1 DGYOQSAUPDVPQH-UHFFFAOYSA-N 0.000 claims description 2
- QBMKVGAHJVUDMD-UHFFFAOYSA-N 5,6-dibromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol hydrochloride Chemical compound Cl.OC=1NC2=CC(Br)=C(Br)C=C2C=1C(N=C1)=CC=C1CN1CCOCC1 QBMKVGAHJVUDMD-UHFFFAOYSA-N 0.000 claims description 2
- CEVWVQYKVWVJFO-UHFFFAOYSA-N 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide hydrochloride Chemical compound Cl.OC=1NC2=CC=C([N+]([O-])=O)C=C2C=1C(N=C1)=CC=C1C(=O)NCCN1CCOCC1 CEVWVQYKVWVJFO-UHFFFAOYSA-N 0.000 claims description 2
- KFXQVCKZFXCCCN-UHFFFAOYSA-N 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-N-methyl-N-(1-methylpiperidin-4-yl)pyridine-3-carboxamide hydrochloride Chemical compound Cl.C=1C=C(C=2C3=CC(=CC=C3NC=2O)[N+]([O-])=O)N=CC=1C(=O)N(C)C1CCN(C)CC1 KFXQVCKZFXCCCN-UHFFFAOYSA-N 0.000 claims description 2
- LLAZTZBIMDHGFQ-UHFFFAOYSA-N 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide hydrochloride Chemical compound Cl.OC=1NC2=CC=C(C#N)C=C2C=1C(N=C1)=CC=C1S(=O)(=O)NCCN1CCCC1 LLAZTZBIMDHGFQ-UHFFFAOYSA-N 0.000 claims description 2
- GFRMJDAREJXJMH-UHFFFAOYSA-N 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methylpyridine-3-carboxamide hydrochloride Chemical compound Cl.N1=CC(C(=O)N(C)CCN(C)C)=CC=C1C1=C(O)NC2=CC=C(C#N)C=C12 GFRMJDAREJXJMH-UHFFFAOYSA-N 0.000 claims description 2
- GECIALRGJBQECL-UHFFFAOYSA-N 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide hydrochloride Chemical compound Cl.C=1C=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=CC=1S(=O)(=O)N(C)CCN1CCCC1 GECIALRGJBQECL-UHFFFAOYSA-N 0.000 claims description 2
- BLTVBQXJFVRPFK-UHFFFAOYSA-N AZD1080 Chemical compound OC=1NC2=CC=C(C#N)C=C2C=1C(N=C1)=CC=C1CN1CCOCC1 BLTVBQXJFVRPFK-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- QVPHTKOEMVVGNO-UHFFFAOYSA-N [6-(2-hydroxy-5-nitro-1H-indol-3-yl)pyridin-3-yl]-morpholin-4-ylmethanone Chemical compound OC=1NC2=CC=C([N+]([O-])=O)C=C2C=1C(N=C1)=CC=C1C(=O)N1CCOCC1 QVPHTKOEMVVGNO-UHFFFAOYSA-N 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 18
- 102000001267 GSK3 Human genes 0.000 claims 4
- 230000007000 age related cognitive decline Effects 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 2
- OJSUZRNVWYHBNS-UHFFFAOYSA-N (2-chloropyridin-4-yl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=NC(Cl)=C1 OJSUZRNVWYHBNS-UHFFFAOYSA-N 0.000 claims 1
- DMXGFDSGVSISBY-UHFFFAOYSA-N 1-(5-bromo-6-chloropyridin-3-yl)sulfonyl-4-methylpiperazine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CN=C(Cl)C(Br)=C1 DMXGFDSGVSISBY-UHFFFAOYSA-N 0.000 claims 1
- JIVHZSMTMHEIIJ-UHFFFAOYSA-N 1-(6-chloropyridin-3-yl)sulfonyl-4-(3-methylbutyl)piperazine Chemical compound C1CN(CCC(C)C)CCN1S(=O)(=O)C1=CC=C(Cl)N=C1 JIVHZSMTMHEIIJ-UHFFFAOYSA-N 0.000 claims 1
- IHNXDZSFVAKMPS-UHFFFAOYSA-N 1-(6-chloropyridin-3-yl)sulfonyl-4-ethylpiperazine Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CC=C(Cl)N=C1 IHNXDZSFVAKMPS-UHFFFAOYSA-N 0.000 claims 1
- APIKVTIQATUVSW-UHFFFAOYSA-N 1-(6-chloropyridin-3-yl)sulfonyl-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1S(=O)(=O)C1=CC=C(Cl)N=C1 APIKVTIQATUVSW-UHFFFAOYSA-N 0.000 claims 1
- KBEVORJYGNBWMO-UHFFFAOYSA-N 1-(6-chloropyridin-3-yl)sulfonyl-4-propan-2-ylpiperazine Chemical compound C1CN(C(C)C)CCN1S(=O)(=O)C1=CC=C(Cl)N=C1 KBEVORJYGNBWMO-UHFFFAOYSA-N 0.000 claims 1
- SYZINCODTQBXFY-UHFFFAOYSA-N 1-[(6-chloro-1-oxidopyridin-1-ium-3-yl)methyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]piperazine Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1N1CCN(CC=2C=[N+]([O-])C(Cl)=CC=2)CC1 SYZINCODTQBXFY-UHFFFAOYSA-N 0.000 claims 1
- ZFTFICPSCQMETJ-UHFFFAOYSA-N 1-[(6-chloro-1-oxidopyridin-1-ium-3-yl)methyl]-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1CC1=CC=C(Cl)[N+]([O-])=C1 ZFTFICPSCQMETJ-UHFFFAOYSA-N 0.000 claims 1
- RMNSNILYZJFJDV-UHFFFAOYSA-N 1-[(6-chloro-1-oxidopyridin-1-ium-3-yl)methyl]-4-phenylpiperazine Chemical compound C1=C(Cl)[N+]([O-])=CC(CN2CCN(CC2)C=2C=CC=CC=2)=C1 RMNSNILYZJFJDV-UHFFFAOYSA-N 0.000 claims 1
- WJQBYCXAXWHZMH-UHFFFAOYSA-N 1-[(6-chloro-1-oxidopyridin-1-ium-3-yl)methyl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1CC1=CC=C(Cl)[N+]([O-])=C1 WJQBYCXAXWHZMH-UHFFFAOYSA-N 0.000 claims 1
- GSWLWKFDOBMBAQ-UHFFFAOYSA-N 1-[(6-chloropyridin-3-yl)methyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1CC1=CC=C(Cl)N=C1 GSWLWKFDOBMBAQ-UHFFFAOYSA-N 0.000 claims 1
- OKPNSSCDBMCCFP-UHFFFAOYSA-N 1-benzyl-4-(6-chloropyridin-3-yl)sulfonylpiperazine Chemical compound C1=NC(Cl)=CC=C1S(=O)(=O)N1CCN(CC=2C=CC=CC=2)CC1 OKPNSSCDBMCCFP-UHFFFAOYSA-N 0.000 claims 1
- YNBXKLREXVZEBN-UHFFFAOYSA-N 1h-indol-2-ol;hydrochloride Chemical compound Cl.C1=CC=C2NC(O)=CC2=C1 YNBXKLREXVZEBN-UHFFFAOYSA-N 0.000 claims 1
- OPOVTRMYALELSR-UHFFFAOYSA-N 2-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]pyridine-4-carboxamide Chemical compound CN(C)CCNC(=O)C1=CC=NC(C=2C3=CC(=CC=C3NC=2O)C#N)=C1 OPOVTRMYALELSR-UHFFFAOYSA-N 0.000 claims 1
- GDZNKWOYWRIHHC-UHFFFAOYSA-N 2-chloro-1-oxido-5-(piperidin-1-ylmethyl)pyridin-1-ium Chemical compound C1=C(Cl)[N+]([O-])=CC(CN2CCCCC2)=C1 GDZNKWOYWRIHHC-UHFFFAOYSA-N 0.000 claims 1
- IHCFCOSDTCWCLH-UHFFFAOYSA-N 2-chloro-1-oxido-5-(pyrrolidin-1-ylmethyl)pyridin-1-ium Chemical compound C1=C(Cl)[N+]([O-])=CC(CN2CCCC2)=C1 IHCFCOSDTCWCLH-UHFFFAOYSA-N 0.000 claims 1
- DQORQTYXMKXZRL-UHFFFAOYSA-N 2-chloro-1-oxido-5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyridin-1-ium Chemical compound C1=C(Cl)[N+]([O-])=CC(CN2CCC(CC2)N2CCCC2)=C1 DQORQTYXMKXZRL-UHFFFAOYSA-N 0.000 claims 1
- JTPDBQZBSVOTBK-UHFFFAOYSA-N 2-chloro-5-[(3-methylpiperidin-1-yl)methyl]-1-oxidopyridin-1-ium Chemical compound C1C(C)CCCN1CC1=CC=C(Cl)[N+]([O-])=C1 JTPDBQZBSVOTBK-UHFFFAOYSA-N 0.000 claims 1
- PBRFZPAJFXECIH-UHFFFAOYSA-N 2-chloro-5-[(4-methylpiperidin-1-yl)methyl]-1-oxidopyridin-1-ium Chemical compound C1CC(C)CCN1CC1=CC=C(Cl)[N+]([O-])=C1 PBRFZPAJFXECIH-UHFFFAOYSA-N 0.000 claims 1
- VQKCOHCRVRPGKM-UHFFFAOYSA-N 2-chloro-n-[2-(dimethylamino)ethyl]pyridine-4-carboxamide Chemical compound CN(C)CCNC(=O)C1=CC=NC(Cl)=C1 VQKCOHCRVRPGKM-UHFFFAOYSA-N 0.000 claims 1
- SYFQOGMYKZJTMV-UHFFFAOYSA-N 2-hydroxy-3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride Chemical compound Cl.C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=C1 SYFQOGMYKZJTMV-UHFFFAOYSA-N 0.000 claims 1
- OZZYJFSOFDTEHW-UHFFFAOYSA-N 2-hydroxy-3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride Chemical compound Cl.C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2C3=CC=C(C=C3NC=2O)C#N)N=C1 OZZYJFSOFDTEHW-UHFFFAOYSA-N 0.000 claims 1
- VAKLQKQVDRLDGI-UHFFFAOYSA-N 2-hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile Chemical compound C1CN(C)CCCN1S(=O)(=O)C1=CC=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=C1 VAKLQKQVDRLDGI-UHFFFAOYSA-N 0.000 claims 1
- JPTJDKSTSDEZNR-UHFFFAOYSA-N 2-oxo-1,3-dihydroindole-5-carbaldehyde Chemical compound O=CC1=CC=C2NC(=O)CC2=C1 JPTJDKSTSDEZNR-UHFFFAOYSA-N 0.000 claims 1
- LGOYLGQYQKXSNC-UHFFFAOYSA-N 3-[(6-chloro-1-oxidopyridin-1-ium-3-yl)methyl-ethylamino]propanenitrile Chemical compound N#CCCN(CC)CC1=CC=C(Cl)[N+]([O-])=C1 LGOYLGQYQKXSNC-UHFFFAOYSA-N 0.000 claims 1
- OTFZDRAEWUHKJF-UHFFFAOYSA-N 3-[5-(4-ethylpiperazin-1-yl)sulfonylpyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile hydrochloride Chemical compound Cl.C1CN(CC)CCN1S(=O)(=O)C1=CC=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=C1 OTFZDRAEWUHKJF-UHFFFAOYSA-N 0.000 claims 1
- RWYGDLZHZRWAGT-UHFFFAOYSA-N 3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-5-(1,3-oxazol-5-yl)-1H-indol-2-ol Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2C3=CC(=CC=C3NC=2O)C=2OC=NC=2)N=C1 RWYGDLZHZRWAGT-UHFFFAOYSA-N 0.000 claims 1
- MFBJGERJCYKORO-UHFFFAOYSA-N 3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-5-pyridin-3-yl-1H-indol-2-ol Chemical compound OC=1NC2=CC=C(C=3C=NC=CC=3)C=C2C=1C(N=C1)=CC=C1CN1CCOCC1 MFBJGERJCYKORO-UHFFFAOYSA-N 0.000 claims 1
- VOHSMAUFLUYXRP-UHFFFAOYSA-N 3-[5-[[cyclohexyl(methyl)amino]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile Chemical compound C=1C=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=CC=1CN(C)C1CCCCC1 VOHSMAUFLUYXRP-UHFFFAOYSA-N 0.000 claims 1
- XRZSTVZROYQDLJ-UHFFFAOYSA-N 4-[(6-chloro-1-oxidopyridin-1-ium-3-yl)methyl]morpholine Chemical compound C1=C(Cl)[N+]([O-])=CC(CN2CCOCC2)=C1 XRZSTVZROYQDLJ-UHFFFAOYSA-N 0.000 claims 1
- MVPGDKVBKNRUMN-UHFFFAOYSA-N 5,6-dibromo-1,3-dihydroindol-2-one Chemical compound C1=C(Br)C(Br)=CC2=C1NC(=O)C2 MVPGDKVBKNRUMN-UHFFFAOYSA-N 0.000 claims 1
- HQMSZHJYVIGPMV-UHFFFAOYSA-N 5-(1,3-oxazol-5-yl)-1,3-dihydroindol-2-one Chemical compound C=1C=C2NC(=O)CC2=CC=1C1=CN=CO1 HQMSZHJYVIGPMV-UHFFFAOYSA-N 0.000 claims 1
- OXXSQYREYZMOEC-UHFFFAOYSA-N 5-(1,3-thiazol-4-yl)-1,3-dihydroindol-2-one Chemical compound C=1C=C2NC(=O)CC2=CC=1C1=CSC=N1 OXXSQYREYZMOEC-UHFFFAOYSA-N 0.000 claims 1
- WXJWBEAGVWVEDM-UHFFFAOYSA-N 5-(2-chloroacetyl)-1,3-dihydroindol-2-one Chemical compound ClCC(=O)C1=CC=C2NC(=O)CC2=C1 WXJWBEAGVWVEDM-UHFFFAOYSA-N 0.000 claims 1
- JFRFROAKFMUGLR-UHFFFAOYSA-N 5-(2-methyl-1,3-thiazol-4-yl)-1,3-dihydroindol-2-one Chemical compound S1C(C)=NC(C=2C=C3CC(=O)NC3=CC=2)=C1 JFRFROAKFMUGLR-UHFFFAOYSA-N 0.000 claims 1
- BMZZYZHCYDDCOL-UHFFFAOYSA-N 5-(azetidin-1-ylmethyl)-2-chloro-1-oxidopyridin-1-ium Chemical compound C1=C(Cl)[N+]([O-])=CC(CN2CCC2)=C1 BMZZYZHCYDDCOL-UHFFFAOYSA-N 0.000 claims 1
- AWOFOOPKKDKSFM-UHFFFAOYSA-N 5-(furan-2-yl)-1,3-dihydroindol-2-one Chemical compound C=1C=C2NC(=O)CC2=CC=1C1=CC=CO1 AWOFOOPKKDKSFM-UHFFFAOYSA-N 0.000 claims 1
- FAABSFPFSLKXNZ-UHFFFAOYSA-N 5-(furan-2-yl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol hydrochloride Chemical compound Cl.OC=1NC2=CC=C(C=3OC=CC=3)C=C2C=1C(N=C1)=CC=C1CN1CCOCC1 FAABSFPFSLKXNZ-UHFFFAOYSA-N 0.000 claims 1
- KFEKDTIWYDGPPQ-UHFFFAOYSA-N 5-(hydroxymethyl)-1,3-dihydroindol-2-one Chemical compound OCC1=CC=C2NC(=O)CC2=C1 KFEKDTIWYDGPPQ-UHFFFAOYSA-N 0.000 claims 1
- IJLCISXHAWDSQV-UHFFFAOYSA-N 5-bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol hydrochloride Chemical compound Cl.OC=1NC2=CC=C(Br)C=C2C=1C(N=C1)=CC=C1CN1CCOCC1 IJLCISXHAWDSQV-UHFFFAOYSA-N 0.000 claims 1
- LRXSVYIRRDZVNQ-UHFFFAOYSA-N 5-pyridin-3-yl-1,3-dihydroindol-2-one Chemical compound C=1C=C2NC(=O)CC2=CC=1C1=CC=CN=C1 LRXSVYIRRDZVNQ-UHFFFAOYSA-N 0.000 claims 1
- RXXJBDYWKIOAPJ-UHFFFAOYSA-N 5-thiophen-2-yl-1,3-dihydroindol-2-one Chemical compound C=1C=C2NC(=O)CC2=CC=1C1=CC=CS1 RXXJBDYWKIOAPJ-UHFFFAOYSA-N 0.000 claims 1
- ANSNPHYKHZDIDV-UHFFFAOYSA-N 6-chloro-3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-1H-indol-2-ol hydrochloride Chemical compound Cl.C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2C3=CC=C(Cl)C=C3NC=2O)N=C1 ANSNPHYKHZDIDV-UHFFFAOYSA-N 0.000 claims 1
- TWQCVSNYPXULNR-UHFFFAOYSA-N 6-chloro-n-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide Chemical compound CCN1CCCC1CNS(=O)(=O)C1=CC=C(Cl)N=C1 TWQCVSNYPXULNR-UHFFFAOYSA-N 0.000 claims 1
- PKAUILNPLGACNA-UHFFFAOYSA-N 6-chloro-n-[2-(dimethylamino)ethyl]-n-ethylpyridine-3-sulfonamide Chemical compound CN(C)CCN(CC)S(=O)(=O)C1=CC=C(Cl)N=C1 PKAUILNPLGACNA-UHFFFAOYSA-N 0.000 claims 1
- HHSJABZQGJTKFW-UHFFFAOYSA-N 6-chloro-n-[2-(dimethylamino)ethyl]pyridine-3-sulfonamide Chemical compound CN(C)CCNS(=O)(=O)C1=CC=C(Cl)N=C1 HHSJABZQGJTKFW-UHFFFAOYSA-N 0.000 claims 1
- MCSUJOOFZWBSEO-UHFFFAOYSA-N 6-chloro-n-methyl-n-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide Chemical compound C=1C=C(Cl)N=CC=1S(=O)(=O)N(C)CCN1CCCC1 MCSUJOOFZWBSEO-UHFFFAOYSA-N 0.000 claims 1
- VNMAHKOLWWAAHE-UHFFFAOYSA-N N-[(1-ethylpyrrolidin-2-yl)methyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)pyridine-3-carboxamide hydrochloride Chemical compound Cl.CCN1CCCC1CNC(=O)C1=CC=C(C=2C3=CC(=CC=C3NC=2O)[N+]([O-])=O)N=C1 VNMAHKOLWWAAHE-UHFFFAOYSA-N 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- KNAGMHCIILIDOU-UHFFFAOYSA-N OC=1NC2=CC=C(C=3C=NC=CC=3)C=C2C=1C([N+](=C1)[O-])=CC=C1CN1CCOCC1 Chemical compound OC=1NC2=CC=C(C=3C=NC=CC=3)C=C2C=1C([N+](=C1)[O-])=CC=C1CN1CCOCC1 KNAGMHCIILIDOU-UHFFFAOYSA-N 0.000 claims 1
- GFIQRWDEXWMTCS-UHFFFAOYSA-N OC=1NC2=CC=C(C=3OC=CC=3)C=C2C=1C([N+](=C1)[O-])=CC=C1CN1CCOCC1 Chemical compound OC=1NC2=CC=C(C=3OC=CC=3)C=C2C=1C([N+](=C1)[O-])=CC=C1CN1CCOCC1 GFIQRWDEXWMTCS-UHFFFAOYSA-N 0.000 claims 1
- VZDDMDDGEIAVJR-UHFFFAOYSA-N OC=1NC2=CC=C(C=3SC=CC=3)C=C2C=1C([N+](=C1)[O-])=CC=C1CN1CCOCC1 Chemical compound OC=1NC2=CC=C(C=3SC=CC=3)C=C2C=1C([N+](=C1)[O-])=CC=C1CN1CCOCC1 VZDDMDDGEIAVJR-UHFFFAOYSA-N 0.000 claims 1
- KCKSHYCEWFJNIT-UHFFFAOYSA-N [6-(2-hydroxy-5-nitro-1H-indol-3-yl)pyridin-3-yl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound OC=1NC2=CC=C([N+]([O-])=O)C=C2C=1C(N=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 KCKSHYCEWFJNIT-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- MTDZOMKWYKURBV-UHFFFAOYSA-N ethyl 6-(5-cyano-2-hydroxy-1H-indol-3-yl)pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OCC)=CC=C1C1=C(O)NC2=CC=C(C#N)C=C12 MTDZOMKWYKURBV-UHFFFAOYSA-N 0.000 claims 1
- NFRTTZRKBUWUQE-UHFFFAOYSA-N n-[(6-chloro-1-oxidopyridin-1-ium-3-yl)methyl]-1-(4-chlorophenyl)-n-methylmethanamine Chemical compound C=1C=C(Cl)[N+]([O-])=CC=1CN(C)CC1=CC=C(Cl)C=C1 NFRTTZRKBUWUQE-UHFFFAOYSA-N 0.000 claims 1
- XDTJXISTKHKAPQ-UHFFFAOYSA-N n-[(6-chloro-1-oxidopyridin-1-ium-3-yl)methyl]-n-methylaniline Chemical compound C=1C=CC=CC=1N(C)CC1=CC=C(Cl)[N+]([O-])=C1 XDTJXISTKHKAPQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 27
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 125000001475 halogen functional group Chemical group 0.000 description 20
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 229910000019 calcium carbonate Inorganic materials 0.000 description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 150000003973 alkyl amines Chemical class 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 150000001340 alkali metals Chemical class 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 125000002883 imidazolyl group Chemical group 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 125000002971 oxazolyl group Chemical group 0.000 description 5
- 125000003373 pyrazinyl group Chemical group 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 125000000168 pyrrolyl group Chemical group 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 125000002877 alkyl aryl group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 230000026030 halogenation Effects 0.000 description 4
- 238000005658 halogenation reaction Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 125000001786 isothiazolyl group Chemical group 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 108010001483 Glycogen Synthase Proteins 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- FHCSBLWRGCOVPT-UHFFFAOYSA-N AZD2858 Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C(=O)NC=2C=NC=CC=2)C=C1 FHCSBLWRGCOVPT-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000004928 piperidonyl group Chemical group 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QFJWLSYVRJXJKO-WLHGVMLRSA-N (E)-but-2-enedioic acid 2-hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCCN1S(=O)(=O)c1ccc(-c2c([nH]c3ccc(cc32)C#N)O)nc1 QFJWLSYVRJXJKO-WLHGVMLRSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- JJAHGJDXTZIKLJ-UHFFFAOYSA-N 2-hydroxy-3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-1H-indole-5-carbonitrile Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=C1 JJAHGJDXTZIKLJ-UHFFFAOYSA-N 0.000 description 1
- LQNNIYIDKIZEQU-UHFFFAOYSA-N 2-hydroxy-3-[5-[(N-methylanilino)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile Chemical compound C=1C=C(C=2C3=CC(=CC=C3NC=2O)C#N)N=CC=1CN(C)C1=CC=CC=C1 LQNNIYIDKIZEQU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- CRTXDPDZYSXKBR-UHFFFAOYSA-N 3-[5-(4-benzylpiperazin-1-yl)sulfonylpyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile Chemical compound OC=1NC2=CC=C(C#N)C=C2C=1C(N=C1)=CC=C1S(=O)(=O)N(CC1)CCN1CC1=CC=CC=C1 CRTXDPDZYSXKBR-UHFFFAOYSA-N 0.000 description 1
- LCJSFFYXNSCWRH-UHFFFAOYSA-N 3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-5-nitro-1H-indol-2-ol hydrochloride Chemical compound Cl.OC=1NC2=CC=C([N+]([O-])=O)C=C2C=1C(N=C1)=CC=C1CN1CCOCC1 LCJSFFYXNSCWRH-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- JFAZPILCCXHAQY-UHFFFAOYSA-N 6-chloro-3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-1H-indol-2-ol Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2C3=CC=C(Cl)C=C3NC=2O)N=C1 JFAZPILCCXHAQY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010031852 Pyruvate Synthase Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- HXELGNKCCDGMMN-UHFFFAOYSA-N [F].[Cl] Chemical compound [F].[Cl] HXELGNKCCDGMMN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000009579 hair morphogenesis Effects 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 210000002511 neuropil thread Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- UVBXZOISXNZBLY-UHFFFAOYSA-L palladium(2+);triphenylphosphane;diacetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UVBXZOISXNZBLY-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- OBLVPWTUALCMGD-UHFFFAOYSA-N pyridin-1-ium-3-carboxamide;chloride Chemical compound Cl.NC(=O)C1=CC=CN=C1 OBLVPWTUALCMGD-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200979A SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | New compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200407665B true ZA200407665B (en) | 2005-08-29 |
Family
ID=20287447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200407665A ZA200407665B (en) | 2002-03-28 | 2004-09-22 | New compounds. |
Country Status (32)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302546D0 (sv) * | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
| US20040067985A1 (en) * | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US8046280B2 (en) * | 2005-06-10 | 2011-10-25 | Pioneer Hi-Bred International, Inc. | Method for using environmental classification to assist in financial management and services |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| SA07280004B1 (ar) * | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
| US20090221576A1 (en) * | 2006-02-02 | 2009-09-03 | Astrazeneca Ab Global Intellectual Property | Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts |
| WO2007089193A1 (en) * | 2006-02-02 | 2007-08-09 | Astrazeneca Ab | A process for preparing 2-hydroxy-3- [5- (morpholin-4-ylmethyl)pyridin-2-yl] lh-indole-5-carbonitrile as a free base or salts thereof |
| WO2007100282A1 (en) * | 2006-02-28 | 2007-09-07 | Astrazeneca Ab | New salts of an indole derivative and their use in medicine |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007120102A1 (en) * | 2006-04-19 | 2007-10-25 | Astrazeneca Ab | New substituted oxindole derivatives |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20080086340A1 (en) * | 2006-10-04 | 2008-04-10 | Pioneer Hi-Bred International, Inc. | Crop quality insurance |
| EA200970361A1 (ru) | 2006-10-09 | 2010-02-26 | Такеда Фармасьютикал Компани Лимитед | Ингибиторы киназы |
| EP2091943B1 (en) | 2006-10-21 | 2013-11-20 | AbbVie Deutschland GmbH & Co KG | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| US8417534B2 (en) | 2006-12-29 | 2013-04-09 | Pioneer Hi-Bred International, Inc. | Automated location-based information recall |
| US8101750B2 (en) | 2007-04-18 | 2012-01-24 | Astrazeneca Ab | Process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile 701 |
| WO2009017454A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| WO2009017455A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
| WO2009017452A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New crystalline forms of 2 -hydroxy- 3- [5- (morpholin- 4- ylmethyl) pyridin-2-yl] ih- indole- 5 -carbonitrile citrate |
| HUE030774T2 (hu) * | 2007-09-06 | 2017-05-29 | Boston Biomedical Inc | Kinázinhibitorokból álló készítmények és felhasználásuk a rák és a kinázokhoz kapcsolódó más betegségek kezelésére |
| US20090291982A1 (en) * | 2008-05-22 | 2009-11-26 | Astrazeneca Ab | New Substituted Oxindole Derivative 352 |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| WO2010143803A2 (en) * | 2009-06-08 | 2010-12-16 | Industry Foundation Of Chonnam National University | New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same |
| JP2011178752A (ja) * | 2010-03-03 | 2011-09-15 | Nagoya Univ | 含窒素複素環化合物及びその製造方法 |
| WO2012041814A1 (en) | 2010-09-27 | 2012-04-05 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| MX2013006467A (es) | 2010-12-09 | 2013-10-01 | Amgen Inc | Compuestos biciclicos como inhibidores pim. |
| MX2013006694A (es) | 2010-12-21 | 2013-07-29 | Bayer Ip Gmbh | Procedimiento para producir oxindoles sustituidos con triazinilo. |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP2688886A1 (en) | 2011-03-22 | 2014-01-29 | Amgen Inc. | Azole compounds as pim inhibitors |
| HUE049377T2 (hu) | 2013-03-14 | 2020-09-28 | Brigham & Womens Hospital Inc | Készítmények és eljárások epiteliális õssejtek expanziójára és tenyésztésére |
| JP2017524739A (ja) | 2014-07-17 | 2017-08-31 | アンセルムＩｎｓｅｒｍ | 神経筋接合部関連疾患の処置方法 |
| CN107073042A (zh) | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法 |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| JP2019506153A (ja) | 2016-01-08 | 2019-03-07 | マサチューセッツ インスティテュート オブ テクノロジー | 分化した腸内分泌細胞およびインスリン産生細胞の作製 |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| RU2648820C2 (ru) * | 2016-04-14 | 2018-03-28 | Общество с ограниченной ответственностью "Научно-исследовательский центр "Парк активных молекул" | Средство, обладающее противоклоногенной активностью в отношении опухолевых клеток человека |
| AU2017386417B2 (en) | 2016-12-30 | 2022-07-14 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| CN108440401A (zh) * | 2018-04-13 | 2018-08-24 | 华东理工大学 | 5-[(4-乙基哌嗪-1-基)甲基]吡啶-2-胺的制备方法 |
| EP3837351A1 (en) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| AU2019321641A1 (en) | 2018-08-17 | 2021-04-15 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating Jag-1 |
| JP2022520671A (ja) | 2019-02-08 | 2022-03-31 | フリークエンシー・セラピューティクス・インコーポレイテッド | 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ192948A (en) * | 1979-03-09 | 1982-02-23 | Ishihara Sangyo Kaisha | Preparation of beta-trifuloromethyl-pyridine derivatives directly from beta-picoline |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5565580A (en) | 1994-01-27 | 1996-10-15 | Neurosearch A/S | Glutamate Antagonists |
| JP2890267B2 (ja) | 1994-02-23 | 1999-05-10 | ファイザー インク． | ４−ヘテロサイクリル−置換キナゾリン誘導体、その調製法および抗癌剤としてのその使用法 |
| TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| DE69838172T2 (de) * | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| AU5301199A (en) | 1998-08-20 | 2000-03-14 | Sumitomo Pharmaceuticals Company, Limited | Oxindole derivatives as growth hormone releasers |
| WO2000071129A1 (en) | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| AU770600B2 (en) * | 1999-10-07 | 2004-02-26 | Amgen, Inc. | Triazine kinase inhibitors |
| US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
| EP1136493A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives |
| ATE284885T1 (de) * | 2000-07-27 | 2005-01-15 | Hoffmann La Roche | 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren |
| HUP0303559A3 (en) | 2000-10-13 | 2006-02-28 | Bristol Myers Squibb Co | Selective maxi-k-potassium channel openers functional under conditions of high intracellular calcium concentration and uses thereof |
| SE0104341D0 (sv) * | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
| SE0104340D0 (sv) * | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| TW200301123A (en) * | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| DE60221283T2 (de) * | 2001-12-21 | 2008-03-20 | Astrazeneca Ab | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden |
| SE0302546D0 (sv) * | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
| JP2005531609A (ja) * | 2002-06-05 | 2005-10-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤としてのシスインドリル−マレイミド誘導体 |
-
2002
- 2002-03-28 SE SE0200979A patent/SE0200979D0/xx unknown
-
2003
- 2003-03-17 AR ARP030100931A patent/AR038996A1/es unknown
- 2003-03-19 TW TW092106042A patent/TWI330081B/zh not_active IP Right Cessation
- 2003-03-26 SA SA03240054A patent/SA03240054B1/ar unknown
- 2003-03-26 MY MYPI20031117A patent/MY144659A/en unknown
- 2003-03-28 MX MXPA04009163A patent/MXPA04009163A/es active IP Right Grant
- 2003-03-28 EP EP08157461A patent/EP1961748A3/en not_active Withdrawn
- 2003-03-28 NZ NZ534664A patent/NZ534664A/en not_active IP Right Cessation
- 2003-03-28 RU RU2004125146/04A patent/RU2338742C2/ru not_active IP Right Cessation
- 2003-03-28 CN CNA2006101537141A patent/CN1923812A/zh active Pending
- 2003-03-28 UA UA20040806742A patent/UA79447C2/uk unknown
- 2003-03-28 JP JP2003580319A patent/JP3989444B2/ja not_active Expired - Fee Related
- 2003-03-28 BR BR0308196-6A patent/BR0308196A/pt not_active IP Right Cessation
- 2003-03-28 ES ES03745498T patent/ES2316784T3/es not_active Expired - Lifetime
- 2003-03-28 KR KR1020047015389A patent/KR101014525B1/ko not_active IP Right Cessation
- 2003-03-28 UY UY27740A patent/UY27740A1/es not_active Application Discontinuation
- 2003-03-28 PL PL372966A patent/PL211096B1/pl not_active IP Right Cessation
- 2003-03-28 CA CA2476343A patent/CA2476343C/en not_active Expired - Fee Related
- 2003-03-28 DE DE60325032T patent/DE60325032D1/de not_active Expired - Lifetime
- 2003-03-28 AT AT03745498T patent/ATE416171T1/de active
- 2003-03-28 IL IL16389403A patent/IL163894A0/xx unknown
- 2003-03-28 WO PCT/SE2003/000508 patent/WO2003082853A1/en active Application Filing
- 2003-03-28 EP EP03745498A patent/EP1492785B9/en not_active Expired - Lifetime
- 2003-03-28 DK DK03745498T patent/DK1492785T3/da active
- 2003-03-28 SI SI200331526T patent/SI1492785T1/sl unknown
- 2003-03-28 CN CNB038073897A patent/CN100519550C/zh not_active Expired - Fee Related
- 2003-03-28 PT PT03745498T patent/PT1492785E/pt unknown
- 2003-03-28 AU AU2003216026A patent/AU2003216026B2/en not_active Ceased
- 2003-03-28 US US10/509,268 patent/US7399780B2/en not_active Expired - Lifetime
-
2004
- 2004-09-02 IL IL163894A patent/IL163894A/en not_active IP Right Cessation
- 2004-09-22 ZA ZA200407665A patent/ZA200407665B/en unknown
- 2004-09-27 IS IS7471A patent/IS7471A/is unknown
- 2004-10-19 NO NO20044432A patent/NO329884B1/no not_active IP Right Cessation
-
2005
- 2005-05-17 HK HK05104104.0A patent/HK1071360A1/xx not_active IP Right Cessation
-
2007
- 2007-06-13 JP JP2007155810A patent/JP2007224051A/ja active Pending
-
2008
- 2008-06-17 US US12/140,510 patent/US20090149460A1/en not_active Abandoned
-
2009
- 2009-02-19 CY CY20091100196T patent/CY1108823T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200407665B (en) | New compounds. | |
| AU2003287135B2 (en) | Novel compounds having selective inhibiting effect at GSK3 | |
| US7595319B2 (en) | Compounds having selective inhibiting effect at GSK3 | |
| US7683067B2 (en) | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3) | |
| US20090018130A1 (en) | Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid | |
| US20080255106A1 (en) | Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders | |
| US8933101B2 (en) | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | |
| AU2003287137B2 (en) | Novel compounds having selective inhibiting effect at GSK3 | |
| KR20120047960A (ko) | 글루코키나아제(ｇｋ) 활성화제로서 치환된 벤즈아미드 유도체 |